Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Anjanette Thompson

Nurse Practitioner, Primary Care Greensboro, NC Nurse Practitioner

NPI 1053610170 CMS profile 10978451

1317 N Elm St Ste 7, Greensboro, NC 27401

Open in the dashboard

General payments

$2,870

115 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anjanette Thompson of Greensboro, NC is reported in the CMS Open Payments database as having received $2,870 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $894 38
2024 General $1,089 33
2023 General $887 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anjanette Thompson
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Anjanette Thompson were reported at $894. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Anjanette Thompson Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $887 $163 $53–$481 $160
2024 $1,089 $176 $54–$511 $164
2025 $894 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Lilly USA, LLC $507 17 payments
  2. Novo Nordisk Inc $472 20 payments
  3. Medtronic, Inc. $283 3 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $242 8 payments
  5. AbbVie, Inc. $197 5 payments
  6. AstraZeneca Pharmaceuticals LP $134 8 payments
  7. Astellas Pharma US Inc $124 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $106 5 payments
  9. Corcept Therapeutics $98 5 payments
  10. Novartis Pharmaceuticals Corporation $97 5 payments
  11. Other $610 32 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,870 115 payments
Products named General payments · program years 2023–2025
  1. MOUNJARO $388 10 payments
  2. Ozempic $250 14 payments
  3. Kerendia $242 8 payments
  4. Wegovy $188 5 payments
  5. INTELLIS ADAPTIVESTIM $171 2 payments
  6. VRAYLAR $164 3 payments
  7. Veozah $124 7 payments
  8. YUPELRI $122 4 payments
  9. RYBELSUS $122 11 payments
  10. INCEPTIV $111 1 payment
  11. Other $1,223 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

885

Median for Nurse Practitioner: 389

Drug cost

$165,668

Median for Nurse Practitioner: $21,885

Branded share of claims

35.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 43 $40,279
Jardiance Empagliflozin Brand 60 $38,293
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 35 $26,440
Rybelsus Semaglutide Brand 16 $22,877
Mounjaro Tirzepatide Brand 15 $15,838
Farxiga Dapagliflozin Propanediol Brand 13 $10,045
Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro Brand 25 $4,518
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 23 $662
Albuterol Sulfate Hfa Albuterol Sulfate Brand 28 $588
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 15 $501

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$4,926

Medicare's payments for the services billed

Medicare patients

44

Average age 69

Services billed

75

26 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Heart failure 27%
Ischemic heart disease 27%
Arthritis 27%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $190
$190 15 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $142
$142 — —
VRAYLAR
  • AbbVie, Inc. $100
$100 — —
YUPELRI
  • Mylan Specialty L.P. $84
$84 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record